Last reviewed · How we verify
Non-ARB
Non-ARB is a non-angiotensin II receptor blocker compound developed at Kyoto Prefectural University of Medicine with an undisclosed mechanism of action.
Non-ARB is a non-angiotensin II receptor blocker antihypertensive agent developed by Kyoto Prefectural University of Medicine. Used for Hypertension.
At a glance
| Generic name | Non-ARB |
|---|---|
| Also known as | Conventional anti-hypertensive treatment |
| Sponsor | Kyoto Prefectural University of Medicine |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Without access to detailed pharmacological data on this specific compound, the exact mechanism cannot be reliably determined. The designation 'Non-ARB' suggests it is distinct from angiotensin II receptor blockers, but the actual molecular target and therapeutic mechanism remain unclear from available public information.
Approved indications
Common side effects
Key clinical trials
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- The GUARDIAN Pilot Trial (NA)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Vascular Intervention Strategies Trial for Alzheimer's (PHASE2)
- Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients (NA)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |